Company: SHPH
Filing Date: 2025-01-24
Form Type: 424B3
Source: 0001493152-25-003508
Chunk: 205

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-24
Form: 424B3
Chunk 205
---
 basis and their fair value hierarchy as of December 31, 2023:

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

| December 31, 2023                          |     | Level 1 |           |     | Level 2 |   |     | Level 3 |         |     | Carrying Value |           |
|:-------------------------------------------|:----|:--------|----------:|:----|:--------|:--|:----|:--------|--------:|:----|:---------------|----------:|
| Assets                                     |     |         |           |     |         |   |     |         |         |     |                |           |
| Marketable Securities:                     |     |         |           |     |         |   |     |         |         |     |                |           |
| United States Treasury Bonds               |     | $       | 2,887,215 |     | $       | — |     | $       |       — |     | $              | 2,887,215 |
| Total Assets                               |     | $       | 2,887,215 |     | $       | — |     | $       |       — |     | $              | 2,887,215 |
| Liabilities                                |     |         |           |     |         |   |     |         |         |     |                |           |
| Derivative Liability - Warrants            |     | $       |         — |     | $       | — |     | $       | 410,660 |     | $              |   410,660 |
| Derivative Liability - Accelerated feature |     |         |         — |     |         | — |     |         |   3,852 |     |                |     3,852 |
| Total Liabilities                          |     | $       |         — |     | $       | — |     | $       | 414,512 |     | $              |   414,512 |

| F-30 |

During the year ended December 31, 2022, the Company had non-derivative warrant liabilities that were measured at fair value on a recurring basis. Each of these fair value measurements was considered to be a Level 3 measurement by the Company as they used significant unobservable inputs, such as the Company’s pre-IPO stock price, probability of event occurrence and other management estimates. The key inputs for each of these warrant